{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=high-dose+cytarabine+%28HIDAC%29", "query": { "intervention": "high-dose cytarabine (HIDAC)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 22, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=high-dose+cytarabine+%28HIDAC%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T08:12:05.675Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02768792", "title": "High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia, in Relapse" ], "interventions": [ { "name": "pembrolizumab,", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 38, "start_date": "2016-08-22", "completion_date": "2024-06-20", "has_results": true, "last_update_posted_date": "2024-09-25", "last_synced_at": "2026-10-02T08:12:05.675Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Chapel Hill, North Carolina", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02768792" }, { "nct_id": "NCT02573363", "title": "Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mitoxantrone Hydrochloride", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 25, "start_date": "2015-10-07", "completion_date": "2019-05-03", "has_results": false, "last_update_posted_date": "2020-04-08", "last_synced_at": "2026-10-02T08:12:05.675Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02573363" }, { "nct_id": "NCT01297543", "title": "Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Chronic Myeloid Leukemia", "Myelodysplasia" ], "interventions": [ { "name": "human myeloid progenitor cells", "type": "BIOLOGICAL" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Cellerant Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2011-03", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2016-07-01", "last_synced_at": "2026-10-02T08:12:05.675Z", "location_count": 10, "location_summary": "La Jolla, California • San Francisco, California • Stanford, California + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Beech Grove", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01297543" }, { "nct_id": "NCT00774046", "title": "High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Ara-C", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 32, "start_date": "2002-12", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2014-02-11", "last_synced_at": "2026-10-02T08:12:05.675Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00774046" }, { "nct_id": "NCT01564784", "title": "A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "inotuzumab ozogamicin", "type": "DRUG" }, { "name": "FLAG (fludarabine, cytarabine and G-CSF)", "type": "DRUG" }, { "name": "HIDAC (high dose cytarabine)", "type": "DRUG" }, { "name": "cytarabine and mitoxantrone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 326, "start_date": "2012-08-02", "completion_date": "2017-01-04", "has_results": true, "last_update_posted_date": "2019-01-09", "last_synced_at": "2026-10-02T08:12:05.675Z", "location_count": 96, "location_summary": "La Jolla, California • Los Angeles, California • Orange, California + 39 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01564784" }, { "nct_id": "NCT00565058", "title": "Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "GTI-2040", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Aptose Biosciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 27, "start_date": "2007-08", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2015-07-27", "last_synced_at": "2026-10-02T08:12:05.675Z", "location_count": 7, "location_summary": "San Francisco, California • Atlanta, Georgia • Indianapolis, Indiana + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00565058" }, { "nct_id": "NCT02013167", "title": "Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Standard of Care Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 405, "start_date": "2014-01-03", "completion_date": "2017-03-14", "has_results": true, "last_update_posted_date": "2024-03-05", "last_synced_at": "2026-10-02T08:12:05.675Z", "location_count": 16, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02013167" }, { "nct_id": "NCT00632827", "title": "Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral T-Cell Lymphoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Navelbine", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride Liposome Injection", "type": "DRUG" }, { "name": "Granulocyte-colony stimulating factor (G-CSF)", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Denileukin diftitox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 21, "start_date": "2008-07-01", "completion_date": "2016-06-23", "has_results": true, "last_update_posted_date": "2020-04-27", "last_synced_at": "2026-10-02T08:12:05.675Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00632827" }, { "nct_id": "NCT02101983", "title": "Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cytosine Arabinoside", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "55 Years to 65 Years" }, "enrollment_count": 11, "start_date": "2011-05", "completion_date": "2017-08", "has_results": true, "last_update_posted_date": "2018-06-27", "last_synced_at": "2026-10-02T08:12:05.675Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02101983" }, { "nct_id": "NCT00003079", "title": "Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "bryostatin 1", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "1997-09", "completion_date": "2001-05", "has_results": false, "last_update_posted_date": "2010-02-17", "last_synced_at": "2026-10-02T08:12:05.675Z", "location_count": 3, "location_summary": "New York, New York • Houston, Texas • Richmond, Virginia", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003079" } ] }